|
EP3230298B1
(en)
|
2014-12-08 |
2021-01-20 |
F.Hoffmann-La Roche Ag |
3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
|
|
PT3270915T
(pt)
*
|
2015-03-16 |
2020-06-17 |
H Hoffnabb La Roche Ag |
Tratamento combinado com um agonista do tlr7 e um inibidor da montagem da cápside do vhb
|
|
EP3294746B1
(en)
*
|
2015-05-12 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
|
|
CN107820498B
(zh)
|
2015-06-30 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
CN117402852A
(zh)
|
2016-10-14 |
2024-01-16 |
精密生物科学公司 |
对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
|
|
JP7201598B2
(ja)
*
|
2017-01-06 |
2023-01-10 |
エフ．ホフマン－ラ ロシュ アーゲー |
３位置換５－アミノ－６Ｈ－チアゾロ［４，５－ｄ］ピリミジン－２，７－ジオン化合物の製造法
|
|
JP7125401B2
(ja)
*
|
2017-01-06 |
2022-08-24 |
エフ．ホフマン－ラ ロシュ アーゲー |
［（１Ｓ）－１－［（２Ｓ，４Ｒ，５Ｒ）－５－（５－アミノ－２－オキソ－チアゾロ［４，５－ｄ］ピリミジン－３－イル）－４－ヒドロキシ－テトラヒドロフラン－２－イル］プロピル］アセテートの新しい固形
|
|
US12012421B2
(en)
|
2017-07-07 |
2024-06-18 |
Hoffmann-La Roche Inc. |
Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
|
|
US12012420B2
(en)
|
2017-11-21 |
2024-06-18 |
Hoffmann-La Roche, Inc. |
Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
|
|
WO2019118884A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
ES2962605T3
(es)
|
2018-02-26 |
2024-03-20 |
Gilead Sciences Inc |
Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
DK3801538T3
(en)
|
2018-05-25 |
2025-01-02 |
Primmune Therapeutics Inc |
Tlr7-agonister
|
|
CR20210015A
(es)
|
2018-07-13 |
2021-03-22 |
Hoffmann La Roche |
Oligonucleótidos para modular la expresión de rtel 1
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
BR112021008255A2
(pt)
|
2018-10-31 |
2021-08-03 |
Gilead Sciences, Inc. |
compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
|
|
JP7273172B2
(ja)
|
2018-10-31 |
2023-05-12 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
|
|
JP7287708B2
(ja)
|
2019-02-08 |
2023-06-06 |
プロジェニア インコーポレイテッド |
Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
US12318403B2
(en)
|
2019-03-07 |
2025-06-03 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′-cyclic dinucleotides and prodrugs thereof
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
BR112021025699A2
(pt)
|
2019-06-19 |
2022-03-03 |
Silverback Therapeutics Inc |
Anticorpos anti-mesotelina e imunoconjugados dos mesmos
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
IL315295A
(en)
|
2019-09-30 |
2024-10-01 |
Gilead Sciences Inc |
Hbv vaccines and methods treating hbv
|
|
CR20220282A
(es)
|
2019-11-26 |
2022-11-28 |
Primmune Therapeutics Inc |
Agonistas del tlr7
|
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
WO2021130195A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffmann-La Roche Ag |
Method of treating virus infection using a tlr7 agonist
|
|
AU2020415322A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
|
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
|
CA3170551A1
(en)
|
2020-03-02 |
2021-09-10 |
Yong Taik Lim |
Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
|
|
JP2023518433A
(ja)
|
2020-03-20 |
2023-05-01 |
ギリアード サイエンシーズ， インコーポレイテッド |
４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
|
|
EP4194006A4
(en)
|
2020-08-04 |
2024-12-04 |
Progeneer Inc. |
mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
|
|
WO2022031011A1
(ko)
|
2020-08-04 |
2022-02-10 |
성균관대학교산학협력단 |
동력학적으로 작용하는 아주번트 앙상블
|
|
EP4194010A4
(en)
|
2020-08-04 |
2025-03-26 |
Progeneer Inc. |
Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
|
|
KR20230043877A
(ko)
|
2020-08-05 |
2023-03-31 |
에프. 호프만-라 로슈 아게 |
B형 간염 환자의 올리고뉴클레오티드 치료
|
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AU2022262644A1
(en)
|
2021-04-23 |
2023-11-09 |
Genmab A/S |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
TW202310852A
(zh)
|
2021-05-13 |
2023-03-16 |
美商基利科學股份有限公司 |
ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
|
|
CR20230585A
(es)
|
2021-06-23 |
2024-02-19 |
Gilead Sciences Inc |
Compuestos Moduladores de Diacilglicerol Quinasa.
|
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240023629A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
JP2024544532A
(ja)
|
2021-11-11 |
2024-12-03 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｈｂｖの処置のための医薬組合せ
|
|
WO2025032082A1
(en)
*
|
2023-08-08 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
|
|
WO2025072406A1
(en)
|
2023-09-26 |
2025-04-03 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|